ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

15 July 2021, 07:30 CEST, Belgium: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals (Euronext Brussels: MITRA) announce a new collaboration to utilize the fill and finish capabilities for ExeVir’s innovative therapies at Mithra’s integrated R&D and manufacturing platform, Mithra CDMO.